Dr. Tewari on Bevacizumab in Advanced Cervical Cancer

Krishnansu S. Tewari, MD, a professor of obstetrics and gynecology at the University of California Irvine in Orange, California, discusses the effectiveness of bevacizumab in relapsed and metastatic cervical cancer.

A phase III trial performed by the GOG compared chemotherapy alone to chemotherapy plus bevacizumab. Overall, the median overall survival for patients who received bevacizumab plus chemotherapy was 17.0 months compared 13.3 months. Indicating an effective biologic agent where none previously existed, Tewari explains.

Read more about this study >>>

<<<

View more from the 2013 ASCO Annual Meeting